Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.
Current therapeutic options for myeloid metaplasia with myelofibrosis (MMM) are limited. A pilot study was conducted of autologous peripheral blood stem cell (PBSC) collection in 27, followed by transplantation in 21 patients with MMM. The median age was 59 (range 45-75) years. PBSCs were mobilized at steady state (n = 2), after granulocyte colony-stimulating factor (G-CSF) alone (n = 17), or after anthracycline-cytarabine induction plus G-CSF (n = 8). A median of 11.6 x 10(6) (range 0 to 410 x 10(6)) CD34(+) cells per kilogram were collected. Twenty-one patients then underwent myeloablation with oral busulfan (16 mg/kg) and PBSC transplantation. The median times to neutrophil and platelet recovery after transplantation were 21 (range 10-96) and 21 (range, 13 to > or = 246) days, respectively. Five patients received back-up PBSC infusion because of delayed neutrophil or platelet recovery. The median follow-up is 390 (range 70-1623) days after transplantation, and the 2-year actuarial survival is 61%. After transplantion, 6 patients died: 3 of nonrelapse causes (1 within 100 days of PBSC infusion) and 3 of disease progression. Erythroid response (hemoglobin > or = 100 g/L [10 gm/dL] without transfusion for > or = 8 weeks) occurred in 10 of 17 anemic patients. Four of 8 patients with a platelet count less than 100 x 10(9)/L (100 000/microL) responded with a durable platelet count more than 100 x 10(9)/L (100 000/microL). Symptomatic splenomegaly improved in 7 of 10 patients. It is concluded that (1) PBSC collection was feasible and stable engraftment occurred after transplantation in most patients with MMM, (2) myeloablation with busulfan was associated with acceptable toxicity, (3) a significant proportion of patients derived clinical benefit after treatment, and (4) further investigation of this novel approach is warranted. (Blood. 2001;98:586-593)
Anderson
J E
JE
Division of Hematology, Department of Medicine, University of Texas Health Science Center at San Antonio, TX, USA.
Tefferi
A
A
Craig
F
F
Holmberg
L
L
Chauncey
T
T
Appelbaum
F R
FR
Guardiola
P
P
Callander
N
N
Freytes
C
C
Gazitt
Y
Y
Razvillas
B
B
Deeg
H J
HJ
D000368:Aged; D002066:Busulfan / Q000008:administration & dosage / Q000633:toxicity; D005500:Follow-Up Studies; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000633:toxicity; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality / Q000592:standards*; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D013163:Splenomegaly / Q000139:chemically induced / Q000517:prevention & control; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods / Q000592:standards*; D014182:Transplantation, Autologous / Q000379:methods / Q000592:standards; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor; D002066:Busulfan